Abstract
Background Fascioliasis, caused by Fasciola hepatica and Fasciola gigantica, is a global veterinary problem in livestock and an emerging zoonotic disease in various countries. Here we present prevalence estimates of Fasciola spp. in all hosts involved in the life cycle and identified risk factors associated with Fasciola transmission in northern Vietnam.
Methodology/Principal findings We conducted a cross-sectional survey in a community in Nghe An province where fascioliasis is endemic and inhabitants commonly consume raw vegetables. Applying a simple random and cluster sampling approach, we collected 1,137 stool and 1,390 blood samples from 1,396 human participants. From 664 buffaloes and cattle, we collected 656 fecal and 534 blood samples. We also collected 330 lymnaeid snails and 233 water plant samples. Human and animal fecal samples were examined by copro-microscopy, while blood samples were screened by ELISA to detect Fasciola serum antibodies. We examined infections in snails using PCR and metacercariae on water plants deploying an in-house technique. Descriptive analysis and logistic regression models were applied to estimate the prevalence of and risk factors for Fasciola infections. While the prevalence of Fasciola infections was very low in humans (0% by copro-microscopy; 0.07% by ELISA), it was high in animals (52% by copro-microscopy; 54% by ELISA). In the multivariable analysis, age was the only factor associated with Fasciola infections in animals. Fasciola could not be detected in any of the sampled water plants or lymnaeid snails..
Conclusion/Significance This study indicated a high prevalence of Fasciola infections in animals and a very low prevalence in humans in a rural community in northern Vietnam. It is recommended to implement a control program to reduce the infection rate in buffaloes and cattle. Furthermore, health education activities for livestock owners should be carried out in Fasciola endemic areas.
Author Summary Fascioliasis is a parasitic disease, caused by the flatworms Fasciola hepatica and Fasciola gigantica, affecting the liver of livestock and humans. Although human fascioliasis is known to occur worldwide, it mainly affects the poorest communities in rural areas across subtropical and tropical countries, with recent emergence in countries such as Vietnam. We conducted a cross-sectional survey on Fasciola spp. infections in different hosts (e.g., humans, buffaloes, cattle, water plants, and snails) in a rural community in northern Vietnam. Our results showed a high prevalence of fascioliasis in livestock, and a very low prevalence in humans, in a rural community in Nghe An province. Fasciola could not be detected in the sampled lymnaeid snails and water plants. In livestock, the occurrence of Fasciola infection was associated with increasing age. Treatment of the community livestock population as well as specific awareness campaigns for livestock owners are suggested to reduce disease transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the institutional review boards of both NIMPE in Vietnam (No. 02-2022/HDDD), and the Ghent University Hospital/Faculty of Medicine and Health Sciences, Ghent University in Belgium (No BC-08915).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be made available on acceptance of the manuscript.
